sofosbuvir has been researched along with Chronic Kidney Failure in 37 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 29 (78.38) | 24.3611 |
2020's | 8 (21.62) | 2.80 |
Authors | Studies |
---|---|
Biancone, L; Buggisch, P; Camargo, M; Chuang, WL; Dvory-Sobol, H; Gaggar, A; Hu, TH; Hyland, R; Kirby, BJ; Liu, CH; Lu, S; Mangia, A; Moreno, C; Osinusi, A; Peng, CY; Sise, ME; Su, WW | 1 |
Cheema, SS; Cheema, SUR; Gilani, N; Hussain, G; Rehman, MS | 1 |
Alloway, RR; Eckman, MH; Sherman, KE; Thakar, CV; Woodle, ES | 1 |
Feng, Z; Gao, H; Huang, R; Li, Z; Liang, X; Lin, T; Liu, S; Ma, J; Wang, X; Xu, L; Zhang, L | 1 |
Byrd, K; D'Agata, EMC; Kalligeros, M; Martin, P; Mylonakis, E; Shehadeh, F; Shemin, D | 1 |
De, A; Dhiman, RK; Duseja, A; Kohli, HS; Kumar, V; Mehta, M; Premkumar, M; Ramachandran, R; Ratho, RK; Singh, MP; Singh, V; Taneja, S; Verma, N | 1 |
Martin, P; McQuaid, T; Sise, ME | 1 |
Boudabbous, M; Chaker, H; Gargouri, S; Hmida, MB; Jarraya, F; Kammoun, K; Kissou, FP; Tahri, N; Tchoupe, MD; Toumi, S; Yaich, S | 1 |
De, A; Duseja, A; Mishra, S; Premkumar, M; Roy, A; Singh, V; Taneja, S; Verma, N | 1 |
Bhamidimarri, KR; Burke, G; Chen, L; Ciancio, G; Guerra, G; Kupin, W; Ladino, M; Martin, P; Mattiazzi, A; Pedraza, F; Roth, D | 1 |
Gancedo-Bringas, P; Larrubia-Marfil, JR; Lucendo-Villarín, A; Martínez-Alfaro, E; Moreno-Planas, JM; Morillas-Ariño, J; Patón-Arenas, R; Sáiz-Chumillas, RM; Sánchez-Ruano, JJ; Solera-Muñoz, M; Tébar-Romero, E; Vicente-Gutiérrez, MDM | 1 |
Anvesh, G; Rajesh, G; Raju, N; Raju, SB; Sridhar, N; Surendra, M; Vijay Kiran, B | 1 |
Chen, TY; Dong, J; Gao, H; He, YL; Hu, CH; Liu, JF; Ren, DF; Yan, TT; Yang, SJ; Yang, Y; Zhao, YR; Zhu, L | 1 |
Desai, K; Desai, N; Kabrawala, M; Mehta, R; Nandwani, S; Parekh, V; Shah, J | 1 |
Chawla, Y; De, A; Dhiman, RK; Duseja, A; Gupta, KL; Kohli, HS; Kumar, V; Mehta, M; Ramachandran, R; Taneja, S | 1 |
Aoufi-Rabih, S; Fabrizi, F; García-Agudo, R; González-Corvillo, C; Salgueira-Lazo, M | 1 |
Ladino, M; Roth, D | 1 |
Chuang, WL; Crawford, DHG; Dokmeci, AK; Hamid, SS; Ibrahim, A; Jindal, A; Kanda, T; Kao, JH; Kumar, M; Lau, GKK; Lesmana, CRA; McCaughan, GW; Moriyama, M; Omata, M; Sarin, SK; Sharma, BC; Sollano, J; Wasim, J; Wei, L; Yokosuka, O; Yu, ML | 1 |
Alfieri, CM; Campise, MR; D'Ambrosio, R; Fabrizi, F; Gandolfo, MT; Gendia, M; Lampertico, P; Messa, P | 1 |
Althoff, CE; Bergfeld, L; Brakemeier, S; Budde, K; Duerr, M; Eckardt, KU; Glander, P; Halleck, F; Lehner, LJ; Marticorena Garcia, SR; Sack, I; Schrezenmeier, EV | 1 |
Chen, J; Fang, Z; Li, M; Li, Y; Lin, Q | 1 |
Agarwal, K; Ampuero, J; Ben-Ari, Z; Borgia, SM; Brown, A; Bruck, R; Calleja, JL; Cooper, C; Cramp, ME; Dearden, J; Dvory-Sobol, H; Esteban, R; Fox, R; Foxton, M; Gane, EJ; Haider, S; Hyland, R; Kirby, BJ; Lu, S; Lurie, Y; Markova, S; Meng, A; Osinusi, AO; Rodriguez, CF; Ryder, SD; Shafran, SD; Shaw, D; Willems, B; Yoshida, EM | 1 |
Ahmed, A; Daugherty, TJ; Glenn, JS; Ha, LD; Higgins, JP; Kim, WR; Kumari, R; Luong, H; Perumpail, RB; Pham, EA; Wang, U; Wong, RJ; Younossi, ZM | 1 |
Ahmed, A; Daugherty, TJ; Higgins, JP; Perumpail, RB; Pham, EA; Wong, RJ | 1 |
Adam, P; Bhamidimarri, KR; Christopher, O; Cynthia, L; Czul, F; David, R; Eugene, S; Frank, C; Hernandez, M; Jeffers, L; Kalyan Ram, B; Lennox, J; Levy, C; Maria, H; Martin, P; O'Brien, C; Paul, M; Peyton, A; Roth, D; Schiff, E | 1 |
Chung, RT; Corey, KE; Friedman, LS; Hundemer, GL; Sise, ME; Ufere, N; Wisocky, J | 1 |
Modi, AA; Nazario, HE; Ndungu, M | 1 |
Alric, L; Barange, K; Cointault, O; Del Bello, A; Esposito, L; Izopet, J; Kamar, N; Lavayssière, L; Marion, O; Métivier, S; Ribes, D; Rostaing, L | 1 |
Alkhouri, N; Anthony, S; Guirguis, J; Hanouneh, IA; Rivas, J; Singh, T | 1 |
Pérez Garrido, I; Rodríguez Gil, FJ | 1 |
Ackens, R; Posthouwer, D | 1 |
Burger, D; Gevers, TJ; Kooistra, MP; Richter, C; Schipper-Reintjes, E | 1 |
Amundsen, BM; Chandraker, A; Chung, RT; Chute, D; Curry, MP; Elias, N; Gabardi, S; Hanifi, JM; Heher, EC; Lin, MV; Pavlakis, M; Riella, LV; Rutherford, AE; Sise, ME | 1 |
Blumberg, EA; Doyle, AM; Lee, DH; Sawinski, D | 1 |
Cameron, A; Fenkel, JM; Frank, AM; Shah, AP; Singh, P | 1 |
Hassan, M; Lalos, A; Liriano-Ward, L; Morales, AL; Nair, V; Sang, M; Satoskar, R; Schiano, T; Smith, C; Tierney, A | 1 |
Bansal, SB; Bodh, V; Choudhary, NS; Jain, M; Kumar, A; Saigal, S; Saraf, N; Sharma, R | 1 |
4 review(s) available for sofosbuvir and Chronic Kidney Failure
Article | Year |
---|---|
Efficacy and safety of sofosbuvir in the treatment of hep C among patients on hemodialysis: a systematic review and meta-analysis.
Topics: Antiviral Agents; Hepatitis C; Humans; Kidney Failure, Chronic; Sofosbuvir | 2020 |
Sofosbuvir-based hepatitis C therapies in patients with chronic and end-stage kidney disease.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Renal Dialysis; Renal Insufficiency, Chronic; Sofosbuvir; United States | 2022 |
Sofosbuvir plus velpatasvir combination for the treatment of chronic hepatitis C in patients with end stage renal disease on renal replacement therapy: A systematic review and meta-analysis.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Kidney Failure, Chronic; Renal Replacement Therapy; Sofosbuvir; Treatment Outcome | 2022 |
Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: a systematic review and meta-analysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Prospective Studies; Renal Insufficiency, Chronic; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2019 |
3 trial(s) available for sofosbuvir and Chronic Kidney Failure
Article | Year |
---|---|
Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- a prospective interventional clinical trial.
Topics: Antiviral Agents; Carbamates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Outcome and Process Assessment, Health Care; Prospective Studies; Pyrrolidines; Renal Dialysis; Sofosbuvir; Valine | 2019 |
A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Biopsy, Needle; Calcineurin Inhibitors; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Glucose Intolerance; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Kidney Failure, Chronic; Kidney Transplantation; Lactams, Macrocyclic; Leucine; Liver; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; RNA, Viral; Salvage Therapy; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine; Viral Load; Viral Nonstructural Proteins; Viremia | 2019 |
Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Drug Monitoring; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Kidney Failure, Chronic; Liver Cirrhosis; Male; Middle Aged; Renal Dialysis; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2019 |
30 other study(ies) available for sofosbuvir and Chronic Kidney Failure
Article | Year |
---|---|
Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Female; Fluorenes; Hepatitis C; Humans; Kidney Failure, Chronic; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2021 |
Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients.
Topics: Adult; Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Donor Selection; Drug Combinations; Female; Fluorenes; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Outcome and Process Assessment, Health Care; Postoperative Complications; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Viremia | 2020 |
Effect of Hemodialysis on Efficacy and Pharmacokinetics of Sofosbuvir Coformulated with Either Daclatasvir or Ledipasvir in Patients with End-Stage Renal Disease.
Topics: Adult; Aged; Benzimidazoles; Carbamates; Clinical Trials as Topic; Drug Monitoring; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end-stage renal disease on maintenance haemodialysis.
Topics: Adult; Antiviral Agents; Carbamates; Drug Combinations; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Kidney Failure, Chronic; Macrocyclic Compounds; Male; Middle Aged; Prospective Studies; Renal Dialysis; Sofosbuvir; Sulfonamides; Treatment Outcome | 2021 |
Treatment of chronic hepatitis C with sofosbuvir in a hemodialysis patient: a case report.
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Follow-Up Studies; Genotype; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Sofosbuvir; Sustained Virologic Response | 2021 |
Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Donor Selection; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Postoperative Care; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Tissue Donors; Treatment Outcome; Valine | 2017 |
Influence of baseline MELD score in the efficacy of treatment of hepatitis C with simeprevir and sofosbuvir.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Male; Middle Aged; Models, Theoretical; Prospective Studies; Severity of Illness Index; Simeprevir; Sofosbuvir; Treatment Outcome | 2018 |
Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection in end stage renal disease patients: A prospective observational study.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Renal Dialysis; Sofosbuvir; Treatment Outcome; Young Adult | 2018 |
Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis.
Topics: Acute Disease; Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Pyrrolidines; Renal Dialysis; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2018 |
Preliminary experience with sofosbuvir-based treatment regimens for patients dependent on hemodialysis.
Topics: Antiviral Agents; Benzimidazoles; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Fluorenes; Hepatitis C; Humans; Kidney Failure, Chronic; Renal Dialysis; Sofosbuvir | 2018 |
Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease.
Topics: Adult; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Pyrrolidines; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Valine | 2018 |
Hepatitis C Virus Infection in ESKD Patients.
Topics: Aged; Antiviral Agents; Benzimidazoles; Benzofurans; Drug Combinations; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Kidney Transplantation; Male; Mass Screening; Quinoxalines; Sofosbuvir; Uridine Monophosphate | 2018 |
APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzofurans; Contraindications, Drug; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2019 |
Impact of hepatitis C virus and direct acting antivirals on kidney recipients: a retrospective study.
Topics: Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney; Kidney Failure, Chronic; Kidney Transplantation; Liver; Male; Middle Aged; Patient Safety; Proteinuria; Retrospective Studies; Simeprevir; Sofosbuvir; Sustained Virologic Response | 2019 |
Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Liver Transplantation; Male; Middle Aged; Renal Dialysis; Simeprevir; Sofosbuvir; Transplant Recipients; Treatment Outcome; Viral Load | 2015 |
A New Standard of Care? Standard Dose Sofosbuvir in an HCV-Infected Liver Transplant Recipient Undergoing Hemodialysis.
Topics: Antiviral Agents; Biopsy; Drug Therapy, Combination; End Stage Liver Disease; Hepatitis C; Hepatorenal Syndrome; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Liver Transplantation; Male; Middle Aged; Recurrence; Renal Dialysis; Simeprevir; Sofosbuvir; Time Factors; Treatment Outcome | 2016 |
Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Kidney Failure, Chronic; Male; Middle Aged; Simeprevir; Sofosbuvir | 2015 |
Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Failure, Chronic; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Viral Load | 2015 |
Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 ml/min.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Liver Cirrhosis; Male; Middle Aged; Renal Dialysis; Simeprevir; Sofosbuvir; Sustained Virologic Response; Texas | 2016 |
Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation.
Topics: Antiviral Agents; DNA, Viral; Female; Follow-Up Studies; Glomerular Filtration Rate; Graft Survival; Hepacivirus; Hepatitis C; Humans; Kidney Failure, Chronic; Kidney Function Tests; Kidney Transplantation; Male; Middle Aged; Pilot Projects; Prognosis; Risk Factors; Safety; Sofosbuvir; Viral Load | 2016 |
Sofosbuvir-based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Male; Middle Aged; Ohio; Renal Dialysis; Simeprevir; Sofosbuvir; Sustained Virologic Response | 2016 |
Sofosbuvir antiviral therapy in HCV patients with severe renal failure.
Topics: Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Male; Middle Aged; Severity of Illness Index; Sofosbuvir | 2017 |
Treatment of chronic hepatitis C with direct acting antiviral agents in patients with haemophilia, end-stage liver disease and coinfected with HIV.
Topics: Adult; Antiviral Agents; Carbamates; CD4 Lymphocyte Count; Coinfection; Drug Interactions; Hemophilia A; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Pyrrolidines; RNA, Viral; Sofosbuvir; Treatment Outcome; Valine; Viral Load | 2016 |
Full-dose sofosbuvir and daclatasvir for chronic hepatitis C infection in haemodialysis patients.
Topics: Antiviral Agents; Carbamates; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load | 2016 |
Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Kidney Transplantation; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Transplant Recipients; Treatment Outcome | 2016 |
Successful Posttransplant Treatment of Hepatitis C With Ledipasvir-Sofosbuvir in HIV+ Kidney Transplant Recipients.
Topics: Adult; Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; HIV Infections; Humans; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Postoperative Care; Retrospective Studies; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2017 |
Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens.
Topics: Acetaminophen; Adult; Allografts; Antiviral Agents; Benzimidazoles; Blood-Borne Pathogens; Chemical and Drug Induced Liver Injury; Disease Transmission, Infectious; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Kidney Failure, Chronic; Kidney Transplantation; Liver Transplantation; Male; Middle Aged; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sofosbuvir; Transplant Recipients; Viral Load | 2017 |
Ledipasvir/sofosbuvir is effective and well tolerated in postkidney transplant patients with chronic hepatitis C virus.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Follow-Up Studies; Glomerular Filtration Rate; Graft Survival; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Function Tests; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Prognosis; Retrospective Studies; Risk Factors; Sofosbuvir; Uridine Monophosphate | 2017 |
Efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C patients on dialysis.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Sofosbuvir; Treatment Outcome | 2017 |